Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
NCT03919994 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 338
Last updated 2023-02-02
Summary
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)
Conditions
Sponsors & Collaborators
-
Alkermes, Inc.
lead INDUSTRY
Principal Investigators
-
Alkermes Medical Director · Alkermes, Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-28
- Primary Completion
- 2023-01-04
- Completion
- 2023-01-04
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
NCT00236353 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
NCT01432444 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00210691 ·Status: COMPLETED ·Phase: PHASE3
-
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
NCT00653406 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
NCT01469039 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
NCT00558298 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00246259 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
NCT00337662 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
NCT05779241 ·Status: COMPLETED ·Phase: PHASE3
-
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
NCT01181960 ·Status: COMPLETED
-
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071 ·Status: COMPLETED ·Phase: PHASE4
-
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
NCT03376763 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
NCT00253136 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
NCT03503318 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
NCT00589914 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone
NCT02019329 ·Status: COMPLETED ·Phase: PHASE1
-
A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
NCT00236587 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics
NCT02712463 ·Status: COMPLETED
-
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
NCT00216580 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder
NCT00391222 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
NCT02873208 ·Status: COMPLETED ·Phase: PHASE3
-
Bioavailability of LY03004 and Risperdal® Consta®
NCT02091388 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
NCT00369239 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
NCT02634320 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
NCT00269919 ·Status: COMPLETED ·Phase: PHASE4